The results of the 2023 national medical insurance drug catalogue adjustments were announced today. According to incomplete statistics from the Financial Association, as of press release, 20 A-share companies, including Kanghong Pharmaceutical, Zhongsheng Pharmaceutical, Beta Pharmaceutical, Health Yuan, Yifan Pharmaceutical, Hengrui Pharmaceutical, China Resources Shuanghe, Junshi Biotech, Kangyuan Pharmaceutical, Zejing Pharmaceutical, Haichen Pharmaceutical, Tibet Pharmaceutical, Renfu Pharmaceutical, Shu Taishen, Hisilico, Connbel, Eddy Pharmaceutical, Red Day Pharmaceutical, Microchip Biotech, and Alice, announced after the market that new drugs were introduced, renewed, or adapted for new medical insurance conditions Catalogue of medicines. In terms of COVID-19 drugs, Junshi Biotech announced that Mindewei's indications for adult patients with mild to moderate novel coronavirus infections (COVID-19) were included in the official national health insurance catalogue for the first time. Zhongsheng Pharmaceutical said that laitvir tablets were China's first 3CL monotherapy, an innovative drug with independent intellectual property rights to fight COVID-19 infection. Small financial note: In terms of secondary market performance, Tibet Pharmaceutical closed up 5.92%, Zhongsheng Pharmaceutical rose 5.36%, Haichen Pharmaceutical rose 4%, and Hongri Pharmaceutical rose 3.85%.
恒瑞医药、华润双鹤等二十家上市公司盘后公告药品进入国家医保目录 君实生物和众生药业新冠药品获纳入
Twenty listed companies, including Hengrui Pharmaceutical and China Resources Shuanghe, announced after the market that drugs entered the national health insurance catalogue, Junshi Biotech and Zhongsheng Pharmaceutical's COVID-19 drugs were included
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.